CBIO Catalyst Biosciences Inc.

8.38
-0.12  -1%
Previous Close 8.5
Open 8.46
Price To Book 0.95
Market Cap 100,393,263
Shares 11,980,103
Volume 109,481
Short Ratio
Av. Daily Volume 232,071

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 2 final data released July 7, 2019. Primary endpoint met.
Marzeptacog alfa
Hemophilia
Phase 2b data due 4Q 2019.
Dalcinonacog alfa – DalcA
Hemophilia B
Phase 1 PK trial to be initiated 2Q 2019 with data due 4Q 2019.
Marzeptacog alfa
Hemophilia

Latest News

  1. A Look At Benzinga Pro's Most-Searched Tickers For July 8, 2019
  2. Catalyst Biosciences Meets the Primary Endpoint of Reduction in Annualized Bleeding Rate in the Phase 2 Trial of Subcutaneous Marzeptacog Alfa (Activated) in Patients with Hemophilia A or B with Inhibitors
  3. If You Had Bought Catalyst Biosciences (NASDAQ:CBIO) Stock Three Years Ago, You'd Be Sitting On A 68% Loss, Today
  4. Catalyst Biosciences Announces Oral and Poster Presentations at the International Society on Thrombosis and Haemostasis
  5. Catalyst Biosciences to Present at the Jefferies 2019 Global Healthcare Conference
  6. Catalyst Biosciences Reports First Quarter 2019 Operating & Financial Results and Provides a Corporate Update
  7. Catalyst Biosciences & Mosaic Biosciences Present Preclinical Data on Pegylated CB 2782 for the Treatment of Dry Age-Related Macular Degeneration
  8. Catalyst Biosciences to Present at The Needham & Company 18th Annual Healthcare Conference
  9. Catalyst Biosciences Initiates a Phase 2b Trial of Dalcinonacog Alfa for the Treatment of Hemophilia B
  10. Could The Catalyst Biosciences, Inc. (NASDAQ:CBIO) Ownership Structure Tell Us Something Useful?
  11. Catalyst Biosciences Receives Orphan Designation from the European Commission for Marzeptacog Alfa (Activated)
  12. Catalyst Biosciences Inc (CBIO) Files 10-K for the Fiscal Year Ended on December 31, 2018
  13. Catalyst Biosciences Reports Fourth Quarter and Full-Year 2018 Operating & Financial Results and Provides a Corporate Update
  14. Catalyst Biosciences Announces Poster Presentation at the Association for Research in Vision and Ophthalmology Annual Meeting
  15. New Research: Key Drivers of Growth for Omega Healthcare Investors, Cinedigm, Cardiovascular, Allegiant Travel, Catalyst Biosciences, and ESCO Technologies — Factors of Influence, Major Initiatives and Sustained Production
  16. Catalyst Biosciences Presents Updated Data from Its Phase 2/3 Trial of Subcutaneous Marzeptacog Alfa (Activated) in Individuals with Hemophilia A or B with Inhibitors at the 12th Annual EAHAD Congress
  17. Catalyst Biosciences Announces Preclinical Proof-of-Concept Data of Gene Therapy Candidate CB 2679d-GT for the Treatment of Hemophilia B
  18. Catalyst Biosciences to Present at the Annual BIO CEO & Investor Conference
  19. Catalyst Biosciences Announces Oral and Poster Presentations at the 12th Annual Congress of the European Association for Haemophilia and Allied Disorders
  20. Is Catalyst Biosciences, Inc.’s (NASDAQ:CBIO) Balance Sheet A Threat To Its Future?